Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02890550
Other study ID # 5514
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date April 2014
Est. completion date April 5, 2018

Study information

Verified date June 2019
Source University Hospital, Strasbourg, France
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of the study is to characterize the clinical manifestations of ALMS within the ciliopathies to prevent complications and determine preventive and therapeutic targets.

The investigators believe that the clinical consequences of mutations in the gene result ALMS1 unprecedented protests and the ALMS study should help to be informed, not only about the understanding and decision support other ciliopathies, but also about some common diseases, as some physiopathogenic roads could be common; the rare disease being exacerbated a model of the channel concerned. Secondarily, the clinical data generated by this project will also be used as part of basic research (eg comparison with results in animal models, use of human cells for in vitro studies or transcriptomic ....) (which will be a secondary upgrading to this work).


Recruitment information / eligibility

Status Terminated
Enrollment 75
Est. completion date April 5, 2018
Est. primary completion date April 5, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 2 Years and older
Eligibility Inclusion Criteria for Patients with Alström syndrome:

- Age> 2 years

- Affiliated with a social security scheme

- Informed consent signed

- Retinal dystrophy and proved at least three diagnostic criteria Alström syndrome (Criteria Marshall et al, 2005):

- Early obesity

- Deafness

- Dilated cardiomyopathy

- Type 2 diabetes

- Hypogonadism

- Absence of polydactyly

- Lack of mental retardation

- A family history of the ALMS

- Mutation in the ALMS gene identified

Inclusion Criteria for Related of Alström patients :

- Father / Mother of a patient diagnosed with Alström

- Age greater than 18 years

- Affiliated with a social security scheme

- Informed consent signed

Exclusion Criteria for Patients with Alström syndrome:

- Current pregnancy (a pregnancy test is routinely performed at baseline)

- Pregnant or breastfeeding women

- Intercurrent diseases do not allow the practice exams in protocol

- Subject to exclusion period (determined by a previous study or a study in progress)

Exclusion Criteria for Related of Alström patients :

- Age less than 18 years

- Subject to exclusion period (determined by a previous study or a study in progress)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France CMCO, Hôpitaux Universitaires Schiltigheim
France Centre d'Investigation Clinique, Nouvel Hôpital Civil, Hôpitaux Universitaires Strasbourg
France Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), Hôpitaux Universitaires Strasbourg
France Clinique Psychiatrique, Hôpital Civil, Hôpitaux Universitaires Strasbourg
France Service d'Imagerie 1, Hôpital de Hautepierre, Hôpitaux Universitaires Strasbourg
France Service d'ORL et de Chirurgie Cervico-Faciale, Hôpital de Hautepierre, Hôpitaux Universitaires Strasbourg
France Service de Cardiologie, Nouvel Hôpital Civil, Hôpitaux Universitaires Strasbourg
France Service de Génétique Médicale, Hôpital de Hautepierre, Hôpitaux Universitaires Strasbourg
France Service de Médecine Interne, Endocrinologie et Nutrition, Hôpital de Hautepierre, Hôpitaux Universitaires Strasbourg
France Service de néphrologie et hémodialyse, Hôpital Civil, Hôpitaux Universitaires Strasbourg
France Service de Pédiatrie 1, Hôpital de Hautepierre, Hôpitaux Universitaires Strasbourg
France Service de physiologie et des Explorations Fonctionnelles, Nouvel Hôpital Civil, Hôpitaux Universitaires Strasbourg
France Service de Psychothérapie pour Enfants et Adolescents, Hôpital Civil, Hôpitaux Universitaires Strasbourg
France Service de Radiologie 2, Hôpital de Hautepierre, Hôpitaux Universitaires Strasbourg

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Genetic Diagnosis In this project, 8 clinical research modules covering major medical issues goshawks ALMS (Genetic diagnosis, neurosensory infringement (ophthalmology and ENT (hearing and olfaction) and neuro-cognitive impairment), obesity & diabetes, endocrine achievement, nephrologic achievement, cardiological achievement, pneumologic achievement, reproductive biology). For each module, the current state of knowledge, clinical issues and their impact on the management of short and medium term ALMS patients are detailed. The clinical complications of this disease must be identified rationally and treatment and clinical management optimized on robust foundations for enhanced medical knowledge. The development of targeted therapies will depend on the clinical research data is the basic foundation of work which can then be enriched by the scientific data currently booming in this area. 6 months
Primary Neurosensory infringement Ophtalmology study: consultation with visual acuity evaluation, examination at the slit lamp, intraocular pressure measurement, fundus examination, evaluation of Goldmann visual field, rétinophotography, standard and multifocal electroretinography, color vision, Optical Coherence Tomography (OCT), orthoptic balance
proportion of initial macular involvement and impact on future therapeutic trials (eg retina / age thickness)
consequences of low vision on posterior optical channels (including occipital cortex)
Olfaction study: brushing the nasal mucosa, isotopic mucociliary clearance, olfactometry (test UPSIT) gustometry, audiogram, otoacoustic emissions, auditory evoked potentials
Is the origin of deafness endocochlear only?
OAS are they a predictive test and prognosis?
Are ALMS patients suffering anosmia as for other ciliopathies?
Mobile eyelashes respiratory mucosal abnormalities are they like other ciliopathies?
6 months
Primary Neurocognitive impairment Neurocognitive explorations:
Neuropsychological assessment with cognitive tests, psychiatric evaluation, MRI, to determine if ALMS patients have cognitive impairment.
Validation of a second population of a new innovative battery of neurocognitive tests for the visually impaired.
6 months
Primary Obesity - Diabetes Study of the origin of obesity:
Origin central or peripheral obesity?
Determinism of insulin resistance and diabetes? nutrition consultation, impedance, basal calorimetry and OGTT, food investigation over 3 days and dietary questionnaires, laboratory tests, calorimetry, polysomnography (Embletta), abdominal-pelvic MRI
6 months
Primary Endocrine Achievement Endocrine study:
- Determine the primary endocrine deficiencies of those who are secondary to obesity and metabolic disorders.
OGTT, test LHRH
6 months
Primary Nephrologic achievement Nephrology consultation including water deprivation test and renal ultrasound, to determine what is the primum movens at the renal impairment (glomerular or tubular origin), and if there is a particular component in fibrotic renal disease compared to other ciliopathies.
nephrology consultation, water deprivation test, renal ultrasound
6 months
Primary Cardiological achievement Study of cardiovascular risk factors:
- Which patients have cardiac fibrosis? At what age and what connection with possible cardiomyopathy childhood? Cardiology consultation including echocardiogram, electrocardiogram (ECG), ambulatory blood pressure measurement, cardiac MRI, cardiac great vessels holter doppler
6 months
Primary Pneumologic achievement Respiratory function study:
Are respiratory alterations related to a breach of mobile eyelashes?
Do ALMS patients develop respiratory fibrosis and in which context ? Spirometry, exhaled NO
6 months
Primary Reproductive biology To explain infertility of ALMS patients (men or women) 6 months